Vyriad
10 articles with Vyriad
-
Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 Clinical Study for Metastatic Colorectal Cancer
7/18/2018
Voyager-V1 is being administered to inflame the tumors, and avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.
-
Although it may be almost heresy to say it to venture capitalists and many research scientists, there are other places in the U.S. to form biotech companies than San Francisco and Boston.
-
Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.
-
Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.
5/10/2018
Vyriad announced today the signing of a contract to build out its facility in 25,000 square feet of leased space on the IBM Campus in Rochester, Minnesota.
-
Biotech Startup Vyriad Graduates from Mayo Clinic Incubator to Larger Space
4/13/2017
-
Vyriad Appoints Alvin E. Mcquinn To Board Of Directors
12/7/2016
-
Vyriad Announces Agreement With Imanis Life Sciences For Development Of Theranostic Tests To Predict Responsiveness To Oncolytic Virotherapy
8/16/2016
-
Vyriad Signs Exclusive License Agreement For STING Technology For Development Of Enhanced Oncolytic Virotherapy Treatments
8/5/2016
-
Profectus BioSciences, Inc. And Vyriad Form Global Collaboration To Develop Oncolytic Recombinant VSV (rVSV) Vaccines For Cancer Immunotherapy
3/18/2016
-
Omnis Pharma And Magnis Therapeutics Merge To Form Vyriad, A Clinical-Stage Oncolytic Immunovirotherapy Development Company
3/18/2016